Nancy Ryan Gray's most recent trade in Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B was a trade of 5,783 Non-Qualified Stock Option (right to buy) done . Disclosure was reported to the exchange on June 6, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Ligand Pharmaceuticals, In... | Nancy Ryan Gray | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2025 | 5,783 | 5,783 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | Nancy Ryan Gray | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2025 | 1,209 | 8,094 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharmaceuticals, In... | Nancy Ryan Gray | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 5,444 | 5,444 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | Nancy Ryan Gray | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 1,252 | 6,885 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharmaceuticals, In... | Nancy Ryan Gray | Director | Sale of securities on an exchange or to another person at price $ 83.20 per share. | 09 May 2024 | 934 | 5,633 (0%) | 0% | 83.2 | 77,713 | Common Stock |
| Ligand Pharmaceuticals, In... | Nancy Ryan Gray | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 5,461 | 5,461 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | Nancy Ryan Gray | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 1,142 | 6,567 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharmaceuticals, In... | Nancy Ryan Gray | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Dec 2022 | 3,050 | 3,050 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | Nancy Ryan Gray | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 4,340 | 4,340 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | Nancy Ryan Gray | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 1,004 | 4,706 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharmaceuticals, In... | Nancy Ryan Gray | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2021 | 3,269 | 3,269 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | Nancy Ryan Gray | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2021 | 630 | 3,702 (0%) | 0% | 0 | Common Stock |